[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Item 1 of about 1
1. McCluggage WG, Jamieson T, Dobbs SP, Grey A: Aggressive angiomyxoma of the vulva: Dramatic response to gonadotropin-releasing hormone agonist therapy. Gynecol Oncol; 2006 Mar;100(3):623-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive angiomyxoma of the vulva: Dramatic response to gonadotropin-releasing hormone agonist therapy.
  • BACKGROUND: Aggressive angiomyxoma (AA) is a vulvovaginal mesenchymal neoplasm with a marked tendency to local recurrence but which usually does not metastasise.
  • Most cases exhibit positive immunohistochemical staining with oestrogen receptor (ER) and, or, progesterone receptor (PR).
  • These agents may also be used to effect a reduction in size, so that more conservative surgery can be undertaken.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Goserelin / therapeutic use. Myxoma / drug therapy. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246403.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


Advertisement





Advertisement